Alfredo Sardinas, MD
Rheumatology · Houston, TXNPI 1164719100
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,850 of the $51,995 with a category attached, or 80.5%. GSK accounts for 82.8% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $21,859 and has fallen 89.2% since, to $2,355 in 2025. Among rheumatology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 491 payments — averaging $105.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$43K
- Amgen$3K
- AbbVie$2K
- Novartis$812
- Mallinckrodt Hospital Products Inc.$745
- UCB, Inc.$500
- plus $3K from 19 others
What the payments were for
- Speaking & faculty fees$41,85080%
- Travel & lodging$1330%
- Food & beverage$9,88519%
- Education$1280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 40 | $43,077 |
| Amgen(2 entities) | 132 | $2,759 |
| AbbVie | 78 | $1,589 |
| Novartis | 45 | $812 |
| Mallinckrodt Hospital Products Inc. | 33 | $745 |
| UCB, Inc. | 28 | $500 |
| Johnson & Johnson | 24 | $420 |
| ANI Pharmaceuticals, Inc. | 22 | $411 |
| AstraZeneca(2 entities) | 18 | $317 |
| Lilly USA, LLC | 16 | $259 |
| Radius Health, Inc. | 16 | $200 |
| Octapharma USA, Inc. | 2 | $160 |
| Aurinia Pharma U.S., Inc. | 8 | $137 |
| Boehringer Ingelheim | 6 | $113 |
| Pfizer | 6 | $106 |
| Medtronic | 1 | $79 |
| Pacira Therapeutics, Inc. | 3 | $57 |
| Organon | 5 | $54 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Mylan Institutional Inc. | 1 | $39 |
| Ultragenyx Pharmaceutical Inc. | 1 | $32 |
| Sanofi | 1 | $30 |
| Sobi, Inc | 1 | $24 |
| Invivyd Inc | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,995 in reported general payments places this provider in the 90th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 90 | $682,400 |
| RinvoqUpadacitinib | 100 | $627,399 |
| Simponi AriaGolimumab | 33 | $261,545 |
| Enbrel SureclickEtanercept | 31 | $225,227 |
| Humira PenAdalimumab | 27 | $195,523 |
| Orencia ClickjectAbatacept | 30 | $171,388 |
| OrenciaAbatacept/Maltose | 34 | $153,009 |
| EnbrelEtanercept | 12 | $103,968 |
| KevzaraSarilumab | 24 | $101,377 |
| OtezlaApremilast | 12 | $89,503 |
| Enbrel MiniEtanercept | 12 | $87,508 |
| Taltz AutoinjectorIxekizumab | 11 | $74,853 |
| Xeljanz XrTofacitinib Citrate | 11 | $61,689 |
| ProliaDenosumab | 22 | $36,877 |
| AravaLeflunomide | 12 | $15,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,589 | $627,399100 claims |
| Johnson & JohnsonSimponi Aria | $420 | $261,54533 claims |
| AmgenEnbrel, Otezla, Prolia | $2,759 | $230,34746 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $41 | $153,00934 claims |
| SanofiKevzara | $30 | $101,37724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Houston
- Naureen AlimHouston$397K
- Shervin AssassiHouston$329K
- Tareq Abou-KhamisHouston$116K
- Maureen MayesHouston$84K
- Maria Suarez AlmazorHouston$72K
- John ReveilleHouston$61K
- Michelle EisenbergHouston$53K
- Adnan PeerHouston$49K
- Mujahed AlikhanHouston$41K
- Dianne WollastonHouston$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.